

Constitutional *MLH1* Methylation Is a Major Contributor to Mismatch Repair–Deficient, *MLH1*-Methylated Colorectal Cancer in Patients Aged 55 Years and Younger

Megan P. Hitchins, PhD^{1,2}; Estela Dámaso, PhD^{2,3}; Rocio Alvarez, MS¹; Lisa Zhou, MS¹; Yajing Hu, PhD²; Marcio A. Diniz, PhD⁴; Marta Pineda, PhD^{3,5}; Gabriel Capella, MD, PhD^{3,5}; Rachel Pearlman, MS, CGC^{6,7}; and Heather Hampel, MS, CGC^{6,7,8}

ABSTRACT

Background: Most mismatch repair–deficient (MMRd) colorectal cancer (CRC) cases arise sporadically, associated with somatic *MLH1* methylation, whereas approximately 20% have germline mismatch repair pathogenic variants causing Lynch syndrome (LS). Universal screening of incident CRC uses presence of *MLH1* methylation in MMRd tumors to exclude sporadic cases from germline testing for LS. However, this overlooks rare cases with constitutional *MLH1* methylation (epimutation), a poorly recognized mechanism for LS. We aimed to assess the frequency and age distribution of constitutional *MLH1* methylation among incident CRC cases with MMRd, *MLH1*-methylated tumors. **Methods:** In retrospective population-based studies, we selected all CRC cases with MMRd, *MLH1*-methylated tumors, regardless of age, prior cancer, family history, or *BRAF* V600E status, from the Columbus-area HNPCC study (Columbus) and Ohio Colorectal Cancer Prevention Initiative (OCCPI) cohorts. Blood DNA was tested for constitutional *MLH1* methylation by pyrosequencing and real-time methylation-specific PCR, then confirmed with bisulfite-sequencing. **Results:** Results were achieved for 95 of 98 Columbus cases and all 281 OCCPI cases. Constitutional *MLH1* methylation was identified in 4 of 95 (4%) Columbus cases, ages 34, 38, 52, and 74 years, and 4 of 281 (1.4%) OCCPI cases, ages 20, 34, 50, and 55 years, with 3 showing low-level mosaic methylation. Mosaicism in blood and normal colon, plus tumor loss of heterozygosity of the unmethylated allele, demonstrated causality in 1 case with sample availability. Age stratification showed high rates of constitutional *MLH1* methylation among younger patients. In the Columbus and OCCPI cohorts, respectively, these rates were 67% (2 of 3) and 25% (2 of 8) of patients aged <50 years but with half of the cases missed, and 75% (3 of 4) and 23.5% (4 of 17) of patients aged ≤55 years with most cases detected. **Conclusions:** Although rare overall, a significant proportion of younger patients with *MLH1*-methylated CRC had underlying constitutional *MLH1* methylation. Routine testing for this high-risk mechanism is warranted in patients aged ≤55 years for a timely and accurate molecular diagnosis that will significantly alter their clinical management while minimizing additional testing.

J Natl Compr Canc Netw 2023;21(7):743–752.e11
doi: 10.6004/jnccn.2023.7020



See JNCCN.org for supplemental online content.

Background

Approximately 15% of colorectal cancer (CRC) cases are mismatch repair (MMR)–deficient (MMRd), detected by immunohistochemistry (IHC),¹ microsatellite instability (MSI),² and/or the hypermutator phenotype.³ Most MMRd CRC cases arise sporadically in older patients, associated with acquired (somatic in origin) aberrant methylation of the *MLH1* promoter in the tumor.^{4–6} Approximately 20% of MMRd CRC cases are associated with Lynch syndrome (LS), caused by a germline pathogenic variant within an MMR gene, *MLH1*, *MSH2*, *MSH6*, *PMS2*, or terminal *EPCAM* deletion.⁷ Constitutional *MLH1* methylation (epimutation), characterized by promoter methylation and transcriptional inactivation of a single allele throughout normal tissues, is an alternative and poorly recognized mechanism for LS.⁸ Cases with constitutional *MLH1* methylation have presented with early-onset and/or multiple primary tumors consistent with *MLH1*-LS⁹; hence, clinical management according to *MLH1*-LS guidelines has been suggested for this subgroup.¹⁰

Universal screening of all CRC for MMRd is recommended as standard of care.^{11–16} This stratifies patients by prediction of response to systemic therapies and identifies those warranting genetic testing for LS.^{6,17,18} Current stepwise algorithms entail tumor testing for MMRd by IHC and/or MSI in the first tier.¹² For tumors exhibiting *MLH1* loss and/or MSI, second-tier testing for *MLH1*

¹Bioinformatics and Functional Genomics Center, Department of Biomedical Sciences, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, California; ²Department of Medicine (Oncology), Stanford University, Stanford, California; ³Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, L'Hospitalet de Llobregat, Barcelona, Spain; ⁴Biostatistics and Bioinformatics Research Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California; ⁵Consortium for Biomedical Research in Cancer – CIBERONC, Carlos III Institute of Health, Madrid, Spain; ⁶Department of Internal Medicine, Ohio State University, Columbus, Ohio; ⁷the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio; and ⁸Division of Clinical Cancer Genomics, Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California.

methylation is recommended, and cases with *MLH1* methylation are considered sporadic and hence omitted from follow-up evaluation for LS.^{15,16,19–22} The *BRAF* V600E tumor mutation is sometimes used as a surrogate for *MLH1* methylation, given that it correlates, albeit imperfectly, with somatic-in-origin *MLH1* methylation and is rare in LS-associated CRC.^{22–25} Cases with MMR protein loss and unmethylated *MLH1*, or *BRAF* wild-type, are eligible for LS testing. Next-generation sequencing tumor panels that detect MSI, hypermutator phenotype, and *BRAF* V600E may replace these stepwise algorithms.²⁶ A potential problem with these algorithms is that they may misdiagnose cases with constitutional *MLH1* methylation as common sporadic cases, thereby omitting them from appropriate follow-up testing. In these high-risk cases, the constitutional *MLH1* methylation serves as the “first hit,” predisposing to tumors that exhibit *MLH1* loss, MSI, and *MLH1* methylation—features that overlap with common sporadic cases.^{8,27–34} Furthermore, most cases arise de novo due to a “primary epimutation” with no apparent genetic basis; consequently, carriers tend to have no remarkable family history.^{8,31,35,36} Although constitutional *MLH1* methylation is potentially heritable, few familial cases have been described. These have included families with autosomal dominant inheritance linked to a genetic variant and others with non-Mendelian inheritance without an associated genetic variant.^{34,35,37–46} Thus, differentiating seemingly sporadic cases with constitutional *MLH1* methylation from “true sporadic” cases with somatic *MLH1* methylation poses a clinical and molecular diagnostic challenge.

Constitutional *MLH1* methylation is rare in CRC overall.⁴⁷ However, its frequency and age distribution among incident MMRd, *MLH1*-methylated CRC cases remains unclear because prior screens have been conducted primarily in single-center studies on small sample sizes. Ascertainment biases in estimations of frequency are likely, given the use of different inclusion criteria with respect to age, clinicopathologic characteristics including *BRAF* V600E status, and prior genetic testing. The frequency of constitutional *MLH1* methylation was 3% to 9%^{8,30,35,41,47–50} in patients ascertained via cancer clinics as fulfilling at least one of the clinical criteria in the revised Bethesda guidelines for LS evaluation,⁵¹ with MSI and *MLH1* loss in their tumor and negative germline test results. Marginally higher rates of constitutional *MLH1* methylation were found with inclusion of *MLH1* methylation as a tumor feature, at 3.5% to 15.6%.^{33,47,52}

In this study, we leveraged the biospecimen resources and prior clinicopathologic and molecular results from the population-based Columbus-area HNPCC study (Columbus)^{53,54} and Ohio Colorectal Cancer Prevention Initiative (OCCPI)⁵⁵ cohorts, designed for prospective studies on universal screening for hereditary cancer, to determine the frequency and age distribution of constitutional

MLH1 methylation among incident CRC cases selected solely by the tumor features of MMRd and presence of *MLH1* methylation.

Methods

Patients

The patient selection strategy is shown in supplemental eFigure 1 (available with this article at www.JNCCN.org). The first case series was derived from 1,566 unselected CRC cases in the Columbus cohort (recruited 1999–2004).^{53,54} The second series was derived from 3,310 CRC cases in the OCCPI cohort (recruited 2013–2016).⁵⁵ Eligibility criteria for inclusion in this study were patients whose CRC showed (1) *MLH1* absence and/or MSI-high if IHC was missing/uninterpretable, (2) *MLH1* methylation, and (3) availability of peripheral blood leukocyte (PBL) DNA (Columbus) or whole-blood DNA (OCCPI). We leveraged the existing tumor molecular pathology data from prior universal screening for MMRd and LS to select cases for inclusion, including MMR IHC, MSI status (Bethesda 5-marker panel),⁵¹ and *MLH1* methylation status previously determined using methylation-specific PCR (Columbus)^{5,56,57} or CpG pyrosequencing⁵⁸ (OCCPI) assays. All patients were deidentified before study initiation.

Screen for Constitutional *MLH1* Methylation and Promoter Variants

Bisulfite conversion was performed on 1 μ g of DNA using the EZ DNA Methylation-Gold Kit (Zymo Research), with approximately 50 ng input into each assay. Screening for constitutional *MLH1* methylation was performed using 2 assays previously described for this purpose: (1) quantitative CpG pyrosequencing using the PyroMark Q96 system (Qiagen)^{31,36,59} and (2) high-sensitivity real-time semi-quantitative methylation-specific PCR (qMSP) followed by melt curve analysis (methylation-specific peak at 76.5°C \pm 0.5°C) using the CFX96 Thermal Cycler system (Bio-Rad Laboratories), enabling the detection of low-level mosaicism.^{34–36,42,60} Samples were considered methylation-positive if either assay yielded a signal above the respective limit of detection, at 2.3% for pyrosequencing and percentage of methylated reference (PMR) value at 0.1% for qMSP (supplemental eFigures 2 and 3).^{42,61} Presence of methylation was confirmed by clonal bisulfite sequencing (\geq 24 clones) across a promoter fragment encompassing 16 CpGs and single-nucleotide polymorphism (SNP) c.-93G>A (rs1800734).^{34–36,61} This also allowed allele-specific methylation patterns to be determined in patients heterozygous for this SNP. The *MLH1* CpG island was Sanger sequenced in methylation-positive cases to identify potential genetic variants associated with constitutional *MLH1* methylation.^{34,42}

Statistics

Descriptive statistics were performed using SPSS Statistics, Version 27. Based on a Bayesian approach, posterior probabilities and 95% high-density probability confidence intervals for various rates of detection were calculated as described in supplemental eAppendix 1.

Results

Detection of Constitutional *MLH1* Methylation

Columbus Cohort

Among 105 of 1,566 (6.7%) eligible cases, 98 cases with *MLH1* loss (n=95; 3 had missing data) and/or MSI-high (n=98) plus *MLH1* methylation in their tumor had PBL DNA available (supplemental eFigure 1). Median age at diagnosis was 72 years (range, 34–98 years). Methylation testing was successful for 95 cases, with complete concordance between pyrosequencing and qMSP results. Constitutional *MLH1* methylation was detected in 4 of 95 (4%) of the selected cases, aged 34, 36, 52, and 74 years at diagnosis (Figure 1). Clonal bisulfite sequencing confirmed the presence of constitutional *MLH1* methylation affecting a proportion of alleles in PBL DNA from all 4 cases (supplemental eFigure 6). The levels and allelic patterns of constitutional *MLH1* methylation and clinical, demographic, and molecular pathology features are summarized in Table 1. Patient Columbus-6 had a classic pattern of hemiallelic methylation (approximately half of alleles methylated), consistent with an epimutation affecting a single parental allele. Notably, the other 3 patients (Columbus-1, -2, and -65) had low-level methylation consistent with mosaicism affecting a proportion of cells (Table 1, supplemental eFigure 6). CRC was the first presentation of cancer in all 4 cases. No genetic alterations were identified within the *MLH1* CpG island in the 4 carriers. Only Columbus-65 had a positive family history recorded, which included CRC and/or endometrial cancer in a first-degree relative, but precise details are unknown.

OCCPI Cohort

Eligible CRC cases included 281 of 3,310 (8.5%) with *MLH1* loss (n=280, 1 equivocal was MSI-high) plus *MLH1* methylation in their tumor and had whole-blood DNA available (supplemental eFigure 1).⁵⁵ Median age at diagnosis was 71.7 years (range, 20–93 years). Methylation testing was successful for all 281 cases, with complete concordance between pyrosequencing and qMSP results. Constitutional *MLH1* methylation was detected in 4 of 281 (1.4%) selected cases, aged 20, 34, 50, and 55 years (Figure 1). These were confirmed by clonal bisulfite sequencing (supplemental eFigure 6), as summarized in Table 1. CRC was the first presentation of cancer in all 4 cases. All 4 cases had an unremarkable family history, and no genetic alterations were identified within the *MLH1* CpG island. Patients OCCPI-2,

-10, and -15 had classic hemiallelic constitutional *MLH1* methylation, with methylation levels of approximately 50% measured by pyrosequencing (Figure 1B) and about half of alleles found to be methylated by clonal bisulfite sequencing (supplemental eFigure 6), consistent with epimutation of one parental allele. OCCPI-1 had low-level mosaic (4.2%) constitutional *MLH1* methylation in blood (Figure 1B); he was heterozygous for the c.-93G>A promoter SNP, with methylation affecting about 20% of “G” alleles (supplemental eFigure 6). Together, these data are consistent with monoallelic, mosaic constitutional *MLH1* methylation affecting approximately 8% to 10% of leukocytes. Tumor and paired normal colorectal mucosa (NCM) DNA samples were retrieved for OCCPI-1. Pyrosequencing detected similarly low-level mosaic *MLH1* methylation (2.6%) in NCM, therefore affecting approximately 5% NCM cells (Figure 2A). In the tumor, a high level of methylation (61%) was detected (Figure 2A), and clonal bisulfite sequencing found only “G” alleles at c.-93G>A, which were predominantly methylated (Figure 2B). Sequencing across the *MLH1* promoter showed loss of heterozygosity (LoH) of the unmethylated “A” allele at c.-93G>A in the tumor (Figure 2C). These findings are consistent with constitutional *MLH1* methylation of the “G” allele in a small proportion of cells as the “first hit” predisposing to tumorigenesis, accompanied by somatic LoH of the unmethylated “A” allele as the “second hit.”

Stratification by Age

To determine the optimal age threshold at which screening yielded the highest rate of detection of constitutional *MLH1* methylation with minimal cases missed while also minimizing the number of cases screened overall, we calculated the frequency of constitutional *MLH1* methylation by age and within 5-year age bins for each cohort (Figure 3, Table 2).

Columbus Cohort

Of the 4 cases with constitutional *MLH1* methylation detected, 2 were aged <50 years, an age bin comprising only 3 of 95 (3%) of the cohort, yielding a positive detection rate of 2 of 3 (67%), but with 2 older cases missed. The only patient with unmethylated PBL in the <50 years bin carried the 5' untranslated region promoter variant c.-11C>T (rs776898290).⁵⁴ This variant has been identified in additional suspected LS cases and showed significantly diminished transcriptional activity in promoter reporter assays,⁴² but it remains a variant of uncertain significance. The highest positive detection rate for constitutional *MLH1* methylation at 3 of 4 (75%) was <55 years, an age threshold that comprised only 4 of 95 (4%) of the cohort, but with 1 older case missed. To detect all




Figure 1. Blood-based detection of constitutional *MLH1* methylation by CpG pyrosequencing in CRC cases with MMRd, *MLH1*-methylated tumors. Pyrogram traces are shown for patients with CRC in whom constitutional *MLH1* methylation was detected across 5 CpG sites within the c.-241 to c.-272 sequence (GenBank accession no. NG_007109.2) of the *MLH1* promoter in bisulfite-converted germline DNA. **(A)** *MLH1* methylation was detected in PBL DNA of 4 cases from the Columbus cohort. **(B)** *MLH1* methylation was detected in whole-blood DNA from 4 cases from the OCCPI cohort. **(C)** Illustrative examples of pyrograms from the hypermethylated RKO CRC cell line as positive control and an unmethylated healthy control PBL as a negative control. Methylation is detected by the presence of a peak at the cytosine (C) within each CpG site interrogated (blue bars), whereas unmethylated cytosines are detected as thymine (T) peaks within the same CpG sites, due to the conversion of unmethylated cytosines to uracils using bisulfite treatment. The percentage methylation value at each CpG site appears above each bar. The mean percentage of methylation across all 5 CpG sites is calculated and shown above each pyrogram. The yellow bar indicates a non-CpG cytosine used as a quality control measure to ensure complete bisulfite conversion to T, whereupon this yields a valid test result.

Abbreviations: Columbus, Columbus-area HNPCC study; CRC, colorectal cancer; MMRd, mismatch repair-deficient; OCCPI, Ohio Colorectal Cancer Prevention Initiative; PBL, peripheral blood leukocyte.

Table 1. Demographic and Clinicopathologic Features of CRC Cases With Constitutional MLH1 Methylation Identified as Likely Cause for Their MMRd, MLH1-Methylated Tumor

Identifier	Sex	Race	Cancer History	Age at Diagnosis	FH	MLH1 IHC	MSI-H	BRAF V600E	Constitutional MLH1 Methylation Levels: Pyrosequencing, qMSP (PMR), Clonal bis-seq
Columbus-area HNPCC study cohort									
Columbus-1	M	Black	Ascending colon	34 y	Neg	Absent	Pos	N/T	3.6%, 1.5%, low-level mosaicism (~1% alleles methylated)
Columbus-2	F	White	Splenic flexure	38 y	Neg	Absent	Pos	WT	27.4%, 13.8%, mosaic (~9% alleles methylated)
Columbus-6	M	White	Cecum, synchronous	52 y	Neg	Absent	Pos	N/T	47.6%, 42.9%, hemiallelic (~50% alleles methylated)
Columbus-65	M	White	Ascending colon	74 y	Pos	Absent	Pos	N/T	3.2%, 1.2%, monoallelic and mosaic (methylation on ~11% of "A" alleles at heterozygous c.-93G>A SNP)
OCCPI study cohort									
OCCPI-1	M	White	CRC unspecified	20 y	Neg	Absent	Pos	WT	4.2%, 1.6%, monoallelic and mosaic (methylation on ~20% "G" alleles at heterozygous c.-93G>A SNP)
OCCPI-2	F	White	Ascending colon	34 y	Neg	Absent	Pos	WT	45.6%, 39.5%, hemiallelic (~50% alleles methylated)
OCCPI-10	F	Black	Cecum	50 y	Neg	Absent	Pos	N/T	47.6%, 35.6%, hemiallelic (~50% alleles methylated)
OCCPI-15	M	White	Transverse colon	55 y	Neg	Absent	Pos	WT	50.4%, 50.4%, hemiallelic (~50% alleles methylated)

Monoallelic methylation indicates methylation is linked to a single genetic allele at a heterozygous promoter SNP. Hemiallelic methylation indicates methylation of approximately half of alleles (~50% methylation measured).

Abbreviations: bis-seq, bisulfite sequencing; Columbus, Columbus-area HNPCC study; CRC, colorectal cancer; Dx, diagnosis; F, female; FH, family history; IHC, immunohistochemistry; M, male; MMRd, mismatch repair-deficient; MSI-H, microsatellite instability-high; N/T, not tested; Neg, negative; OCCPI, Ohio Colorectal Cancer Prevention Initiative; PMR, percentage of methylated reference; Pos, positive; qMSP, real-time semiquantitative methylation-specific PCR followed by melt analysis; SNP, single-nucleotide polymorphism; WT, wild-type.

4 cases, screening of 58 of 95 (61%) cases <75 years of age yielded a detection rate of 4 of 58 (7%).

OCCPI Cohort

Constitutional *MLH1* methylation was detected in 2 of 8 (25%) patients aged <50 years, an age bin comprising just 8 of 281 (2.8%) of the cohort, but with 2 older cases missed. The detection rate was 3 of 14 (21%) patients aged <55 years, an age threshold that comprised 14 of 281 (5%) of the cohort, but with 1 case (aged 55 years) missed. Increasing the age threshold to <60 years entailed screening 31 of 281 (11%) patients in the cohort, yielding a detection rate of 4 of 31 (13%), with all 4 cases detected. The youngest age threshold at which all 4 cases were detected was ≤55 years, which entailed screening of 17 of 281 (6%) of the cohort, yielding a positive detection rate of 4 of 17 (23.5%).

Posterior probabilities for various rates of detection were calculated for each cohort to assess the age limit at which an acceptable detection rate was yielded (supplemental eFigure 7 and eTable 1). Assuming testing for constitutional *MLH1* methylation is considered acceptable when it yields a detection rate >10% with very high probability, the age threshold for testing

implementation would be <60 years for the Columbus-area cohort (probability >0.99) and ≤55 years for the OCCPI cohort (probability 0.96).

Discussion

Current universal testing algorithms may result in patients with constitutional *MLH1* methylation going undiagnosed and underserved as the opportunity for a clinical and molecular diagnosis at first presentation of cancer is missed. For routine implementation of additional blood-based methylation testing into the existing universal screening algorithm for MMRd and LS, multiple factors would be taken into consideration, including the rate/probability of detection among those selected for screening and the number (and cost) of additional tests needed to identify each new case. Our study aimed to address the frequency of constitutional *MLH1* methylation among incident MMRd/*MLH1*-methylated CRC cases and whether age at diagnosis could be incorporated into existing algorithms to select patients warranting referral for additional methylation testing to detect this rare high-risk defect.

Our retrospective nested study of the population-based Columbus and OCCPI cohorts selected CRC cases based




Figure 2. Identification of LoH of the unmethylated allele in the tumor of patient OCCPI-1 indicates low-level mosaic constitutional *MLH1* methylation predisposed to CRC development. **(A)** Pyrosequencing in NCM shows low-level methylation at 2.6% in the tissue of tumor origin and confirms high-level methylation in the tumor (60.8%). Legend according to Figure 1. **(B)** Clonal bisulfite sequencing in the tumor. Legend according to supplemental eFigure 6. Although patient OCCPI-1 was heterozygous at the c.-93G>A SNP (rs1800734), only detected “G” alleles were sequenced in the tumor, most of which were methylated. The methylation patterns on individual alleles were repetitive, suggesting clonal expansion from a small number of cells that contained methylated G alleles. **(C)** Sanger sequencing electropherogram across the c.-93G>A SNP site within the *MLH1* promoter is shown in the tumor and paired NCM samples, with the RFU measured at the A and G peaks at the c.-93G>A SNP (indicated by arrows), shown for each allele below. The LoH index in the tumor was calculated with reference to the paired NCM sample as $(A/G_{\text{Tumor}})/(A/G_{\text{NCM}})$, whereby values <0.6 or >1.7 indicate LoH of the A or G allele, respectively. NCM has approximately equal representation of the G and A alleles, consistent with heterozygosity. The tumor shows reduced representation of the A allele (LoH index 0.23), consistent with LoH of the A allele as the “second hit” in the tumor. See supplemental eFigure 6, available with this article at JNCCN.org.

Abbreviations: CRC, colorectal cancer; LoH, loss of heterozygosity; NCM, normal colorectal mucosa; OCCPI, Ohio Colorectal Cancer Prevention Initiative; RFU, relative fluorescence units; SNP, single-nucleotide polymorphism.

solely on tumor molecular features (*MLH1* loss/MSI-high and *MLH1* methylation) used in universal screening algorithms; therefore, it was unbiased with respect to age at diagnosis, tumor *BRAF*V600E status, personal or family history of cancer, or whether prior germline genetic testing had been undertaken. With selection by these key tumor features, constitutional *MLH1* methylation was detected in just 4% (4/95) of Columbus and 1.4% (4/281) of OCCPI cases. This low frequency across all ages is unsurprising, given the rarity of this defect and because *MLH1* methylation is typically somatic in origin in CRC and associated with advanced age. Although the full cohorts of unselected cases were not screened, by extrapolation this makes constitutional *MLH1* methylation extremely rare among unselected CRC series, at 4 of 1,566 (~0.26%) of Columbus cases and 4 of 3,310 (~0.12%) of OCCPI cases. This mechanism also represents a minor fraction (<10%) of LS cases, because MMR germline pathogenic variants were previously identified in 2.8% of Columbus cases and 4% of OCCPI cases.^{53–55} Nevertheless, a key finding of this study was that

after stratification by age at diagnosis, constitutional *MLH1* methylation was a major contributor to incident MMRd, *MLH1*-methylated CRC among younger cases, which, in turn, represented a small fraction of cases overall. This shows that selection by key tumor features with age limitation would incur screening of small numbers. The highest rates of detection of patients with constitutional *MLH1* methylation were 75% (3/4 tested) of those aged <55 years in the Columbus cohort and 25% (2/8 tested) of those aged <50 years in the OCCPI cohort; however, these age thresholds resulted in missed cases. In the OCCPI cohort, increasing the age of testing to ≤ 55 years maintained a high detection rate at 23.5% (4/17 tested), with all 4 cases with constitutional *MLH1* methylation detected and minimal additional screening. The 2022 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Colorectal recommend that testing for constitutional *MLH1* methylation be considered in patients with CRC whose tumor exhibited *MLH1* loss and *MLH1* methylation if it is early onset (occurs at <50 years




Figure 3. Rate of detection of constitutional *MLH1* methylation by age among the Columbus and OCCPI cohorts. **(A)** Histograms showing the number of cases with constitutional *MLH1* methylation detected (orange) among CRC cases with an MMRd, *MLH1*-methylated tumor (blue) tested within 5-year age bins beginning at age <50 years for each cohort. **(B)** Line graphs showing the cumulative percentage of CRC cases tested by age (blue), beginning at age <50 years pooled, with 100% of cases being n=95 for the Columbus cohort and n=281 for the OCCPI cohort. The percentage of cases with constitutional *MLH1* methylation detected among cases tested of the same age, beginning at age <50 years, are shown in orange. In the Columbus cohort the highest detection rate was 75% (3 of 4) at age threshold <55 years, with 1 older case missed. There were no cases aged 55 years at diagnosis in the Columbus cohort; therefore, the same detection rate was observed at ≤55 years. In the OCCPI cohort, the highest detection rate was 25% (2 of 8) cases <50 years, but with 2 cases missed. The youngest age threshold at which all cases were detected was age ≤55 years (<56 years), yielding a detection rate of 23.5% (4 of 17 cases). In both cohorts, screening at age ≤55 years would entail screening of a small fraction of total cases: 4% for the Columbus cohort and 6% of the OCCPI cohort.

Abbreviations: Columbus, Columbus-area HNPCC study; CRC, colorectal cancer; MMRd, mismatch repair-deficient; OCCPI, Ohio Colorectal Cancer Prevention Initiative.

of age) or they have a family history.¹⁶ However, in the 2 cohorts we studied, restricting testing to patients aged <50 years would have resulted in half (4/8) of cases being missed. Furthermore, probands with constitutional *MLH1* methylation often have no family history, as was found for 7 of 8 cases herein, given that epimutations tend to arise de novo. Only the oldest patient had a family history but no apparent underlying genetic variant. The finding of this 74-year-old patient with constitutional *MLH1* methylation illustrates that age-limited screening will result in occasional missed cases. However, given the rarity of this defect, triaging is needed to increase detection rates for routine implementation of screening. By using age ≤55 years at diagnosis as the threshold for referral of incident cases of CRC with MMRd, *MLH1*-methylated tumors for blood-based

methylation testing, most cases with constitutional *MLH1* methylation herein would have been identified with high detection rates (23.5% Columbus, 75% OCCPI) and with minimal cases screened (4% Columbus, 6% OCCPI with MMRd/*MLH1*-methylated tumors). This would provide a timely and correct molecular diagnosis of this defect at first presentation of CRC at an age when intensive surveillance for *MLH1*-LS cancers could result in the prevention or earlier diagnosis of metachronous cancer and potential life-years saved.

The role of low-level mosaic constitutional *MLH1* methylation in cancer predisposition has remained in question. An interesting observation herein was that 3 patients had low-level mosaic constitutional *MLH1* methylation. Although it is plausible that this may confer lower risks for cancer than

Table 2. Detection Rate of Constitutional *MLH1* Methylation as a Function of Age Group Among Patients With MMRd, *MLH1*-Methylated CRC

Age Bin	Epimutation Cases Detected	Sample Size n (% of Cohort)	Detection Rate (95% CI)
Columbus cohort			
<50 y	2 of 4	3 (3%)	66.7% (22.9–99.0)
<55 y^a	3 of 4	4 (4%)	75.0% (34.7–99.7)
<60 y	3 of 4	7 (7%)	42.9% (12.9–75.4)
<65 y	3 of 4	19 (20%)	15.8% (3.2–33.8)
<70 y	3 of 4	39 (41%)	7.7% (1.4–17.4)
<75 y	4 of 4	58 (61%)	6.9% (1.8–14.4)
<80 y	4 of 4	76 (80%)	5.3% (1.3–11.1)
<All ages	4 of 4	95 (100%)	4.2% (1.0–8.9)
OCCPI cohort			
<50 y	2 of 4	8 (2.8%)	25.0% (3.3–55.1)
<55 y	3 of 4	14 (5.0%)	21.4% (4.7–44.0)
≤55 y	4 of 4	17 (6.0%)	23.5% (7.0–44.5)
<60 y	4 of 4	31 (11.0%)	12.9% (3.5–26.0)
<65 y	4 of 4	60 (21.4%)	6.7% (1.7–13.9)
<70 y	4 of 4	108 (38.4%)	3.7% (0.9–7.9)
<75 y	4 of 4	161 (57.3%)	2.5% (0.6–5.3)
<80 y	4 of 4	220 (78.3%)	1.8% (0.4–3.9)
All ages	4 of 4	281 (100%)	1.4% (0.3–3.1)

The detection rate shows the percentage of cases with 95% CI in which constitutional *MLH1* methylation (epimutation) was detected under/at a designated age threshold at diagnosis of CRC exhibiting MMRd and *MLH1* methylation. The optimal age threshold at which minimal screening of cases selected by these tumor features resulted in a high rate of detection, and most carriers of constitutional *MLH1* methylation identified were aged ≤55 years (shown in bold).

Abbreviations: Columbus, Columbus-area HNPCC study; CRC, colorectal cancer; MMRd, mismatch repair-deficient; OCCPI, Ohio Colorectal Cancer Prevention Initiative.

^aThere were no cases in the Columbus cohort aged 55 years; therefore, the rate of detection at age ≤55 years was the same as for age <55 years.

hemiallelic methylation, mosaicism was found in both the oldest (age 74 years) and the youngest (age 20 years) patients. Prior cases with low-level mosaicism have been reported with early-onset and/or multiple primary cancers.^{42,62} Although additional samples were unavailable from Columbus cases, for patient OCCPI-1 (age 20 years), we were able to demonstrate that methylation was present in NCM (tumor tissue of origin), albeit also low level. Furthermore, by tracing allelic representation and methylation at the c.-93G>A SNP in tumor and NCM, we found high levels of monoallelic methylation in the tumor combined with LoH of the unmethylated allele. These findings are consistent with a causal role for mosaic constitutional *MLH1* methylation in early-onset tumorigenesis, whereby monoallelic methylation in the cell(s) of origin is predisposing, followed by somatic LoH of the remaining functional allele.

A limitation of this study was the lack of systematic *BRAF* V600E tumor testing within the cohorts. For 4 of 8 constitutional *MLH1* methylation carriers with available data, all 4 were *BRAF* wild-type (Table 1). This is consistent

with prior case reports suggesting a higher frequency of *BRAF* wild-type, although a few cases with *BRAF* V600E CRC have been reported.^{31,45} Nevertheless, in the absence of tumor *MLH1* methylation results or in universal screening scenarios where tumor *BRAF* V600E testing is used in place of *MLH1* methylation testing, carriers of constitutional *MLH1* methylation may undergo germline genetic testing for LS (on account of *MLH1* loss plus *BRAF* wild-type in their tumor). This will likely yield a negative/uninformative germline test result. Therefore, testing for constitutional *MLH1* methylation should also be considered in patients with CRC aged ≤55 years whose tumor showed *MLH1* loss and *BRAF* wild-type (in the absence of tumor *MLH1* methylation information) if germline genetic testing returns a nonactionable result to correctly diagnose or rule out constitutional *MLH1* methylation. Finally, referral for constitutional *MLH1* methylation testing should also be considered in patients with a clinical history of synchronous or metachronous LS-associated cancers displaying MMRd and *MLH1* methylation at any age.

Conclusions

Our findings provide evidence in support of referral for blood-based testing for constitutional *MLH1* methylation among patients with first presentation of CRC at age ≤ 55 years whose tumor exhibits MMRd and *MLH1* methylation. Given the low prevalence of CRC cases with these tumor features at younger ages, additional methylation testing will be minimal yet likely to yield high rates of detection of constitutional *MLH1* methylation. Currently, CLIA-certified testing for constitutional *MLH1* methylation in the United States is available at the Mayo Clinic, Rochester, Minnesota, which uses a qMSP test similar to one of the screening tests used in this study.

Acknowledgments

We acknowledge the contribution of, and dedicate this work to, Dr. Albert de la Chapelle.

Submitted July 22, 2022; final revision received March 3, 2023; accepted for publication March 9, 2023.

Author contributions: Study design: Hitchins, Hampel. Data generation and analyses: Hitchins, Dámaso, Alvarez, Zhou, Hu, Pearlman, Hampel. Statistical analyses: Hitchins, Diniz. Results interpretation: Hitchins, Diniz, Pineda, Capella, Pearlman, Hampel. Manuscript preparation and review: All authors.

Disclosures: H. Hampel has disclosed serving on an advisory board for Invitae Genetics, Genome Medical, Natera, and Promega; serving as a consultant for 23andMe, GI OnDemand, and AIM Specialty Health; and owning stock or having an ownership interest in Genome Medical and GI OnDemand. The remaining authors have disclosed that they have not received any financial considerations from any person or organization to support the preparation, analysis, results, or discussion of this article.

Funding: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers CA218342 (M.P. Hitchins), as well as CA67941 and CA16058 (H. Hampel); the Cedars-Sinai Medical Center Precision Health Initiative (M.P. Hitchins); Ministerio de Economía y Competitividad (EEBB-I-16-11581, E. Dámaso); and the Spanish Ministry of Science (PID2019-111254RB-I00, M. Pineda; SAF2015-68016-R, G. Capella).

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Correspondence: Megan P. Hitchins, PhD, Cedars-Sinai Medical Center, 8687 Melrose Avenue, Suite 230.84 B (East), West Hollywood, CA 90069. Email: megan.hitchins@cshs.org

References

- Parsons R, Li GM, Longley MJ, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. *Cell* 1993;75:1227–1236.
- Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58:5248–5257.
- Yamamoto H, Imai K. An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine. *Semin Oncol* 2019;46:261–270.
- Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. *Cancer Res* 1998;58:3455–3460.
- Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc Natl Acad Sci USA* 1998;95:6870–6875.
- Ward R, Meagher A, Tomlinson I, et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. *Gut* 2001;48:821–829.
- Peltomäki P. Update on Lynch syndrome genomics. *Fam Cancer* 2016;15:385–393.
- Hitchins M, Williams R, Cheong K, et al. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. *Gastroenterology* 2005;129:1392–1399.
- Hitchins MP. The role of epigenetics in Lynch syndrome. *Fam Cancer* 2013;12:189–205.
- Lynch HT, Snyder CL, Shaw TG, et al. Milestones of Lynch syndrome: 1895–2015. *Nat Rev Cancer* 2015;15:181–194.
- Burt RW, Cannon JA, David DS, et al. Colorectal cancer screening. *J Natl Compr Canc Netw* 2013;11:1538–1575.
- Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. *J Clin Oncol* 2012;30:1058–1063.
- Heald B, Plesec T, Liu X, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing Lynch syndrome in a large academic medical center. *J Clin Oncol* 2013;31:1336–1340.
- Schofield L, Grieu F, Amanuel B, et al. Population-based screening for Lynch syndrome in Western Australia. *Int J Cancer* 2014;135:1085–1091.
- Ness RM, Llor X, Abbadessa B, et al. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3.2022. Accessed November 7, 2022. To view the most recent version, visit <https://www.nccn.org>
- Gupta S, Weiss JM, Axell L, et al. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2022. Accessed July 11, 2022. To view the most recent version, visit <https://www.nccn.org>
- Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015;372:2509–2520.
- Webber EM, Kauffman TL, O'Connor E, et al. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. *BMC Cancer* 2015;15:156.
- Pérez-Carbonell L, Alenda C, Payá A, et al. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. *J Mol Diagn* 2010;12:498–504.
- Nakagawa H, Nagasaka T, Cullings HM, et al. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability. *Oncol Rep* 2009;21:1577–1583.
- Gausachs M, Mur P, Corral J, et al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. *Eur J Hum Genet* 2012;20:762–768.
- McGivern A, Wynter CV, Whitehall VL, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. *Fam Cancer* 2004;3:101–107.
- Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. *Fam Cancer* 2007;6:301–310.
- Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. *J Med Genet* 2004;41:664–668.
- Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. *Clin Cancer Res* 2004;10:191–195.
- Hampel H, Pearlman R, Beightol M, et al. Assessment of tumor sequencing as a replacement for Lynch syndrome screening and current molecular tests for patients with colorectal cancer. *JAMA Oncol* 2018;4:806–813.
- Gazzoli I, Loda M, Garber J, et al. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the

- resulting microsatellite instability-high tumor. *Cancer Res* 2002;62:3925–3928.
28. Miyakura Y, Sugano K, Akasu T, et al. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. *Clin Gastroenterol Hepatol* 2004;2:147–156.
 29. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. *Nat Genet* 2004;36:497–501.
 30. Valle L, Carbonell P, Fernandez V, et al. MLH1 germline epimutations in selected patients with early-onset non-polyposis colorectal cancer. *Clin Genet* 2007;71:232–237.
 31. Goel A, Nguyen TP, Leung HC, et al. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. *Int J Cancer* 2011;128:869–878.
 32. Auclair J, Vaissière T, Desseigne F, et al. Intensity-dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles. *Genes Chromosomes Cancer* 2011;50:178–185.
 33. Pineda M, Mur P, Iñiesta MD, et al. MLH1 methylation screening is effective in identifying epimutation carriers. *Eur J Hum Genet* 2012;20:1256–1264.
 34. Hitchins MP, Rapkins RW, Kwok CT, et al. Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5'UTR. *Cancer Cell* 2011;20:200–213.
 35. Hitchins MP, Wong JJ, Suthers G, et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. *N Engl J Med* 2007;356:697–705.
 36. Hitchins MP, Owens SE, Kwok CT, et al. Identification of new cases of early-onset colorectal cancer with an MLH1 epimutation in an ethnically diverse South African cohort. *Clin Genet* 2011;80:428–434.
 37. Kwok CT, Vogelaa IP, van Zelst-Stams WA, et al. The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. *Eur J Hum Genet* 2014;22:617–624.
 38. Leclerc J, Flament C, Lovecchio T, et al. Diversity of genetic events associated with MLH1 promoter methylation in Lynch syndrome families with heritable constitutional epimutation. *Genet Med* 2018;20:1589–1599.
 39. Morak M, Schackert HK, Rahnner N, et al. Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC. *Eur J Hum Genet* 2008;16:804–811.
 40. Morak M, Koehler U, Schackert HK, et al. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. *J Med Genet* 2011;48:513–519.
 41. Gylling A, Ridanpää M, Vierimaa O, et al. Large genomic rearrangements and germline epimutations in Lynch syndrome. *Int J Cancer* 2009;124:2333–2340.
 42. Ward RL, Dobbins T, Lindor NM, et al. Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the Colon Cancer Family Registry. *Genet Med* 2013;15:25–35.
 43. Cini G, Carnevali I, Quaia M, et al. Concomitant mutation and epimutation of the MLH1 gene in a Lynch syndrome family. *Carcinogenesis* 2015;36:452–458.
 44. Morak M, Ibsler A, Keller G, et al. Comprehensive analysis of the MLH1 promoter region in 480 patients with colorectal cancer and 1150 controls reveals new variants including one with a heritable constitutional MLH1 epimutation. *J Med Genet* 2018;55:240–248.
 45. Crépin M, Dieu MC, Lejeune S, et al. Evidence of constitutional MLH1 epimutation associated to transgenerational inheritance of cancer susceptibility. *Hum Mutat* 2012;33:180–188.
 46. Sloane MA, Nunez AC, Packham D, et al. Mosaic epigenetic inheritance as a cause of early-onset colorectal cancer. *JAMA Oncol* 2015;1:953–957.
 47. Castillejo A, Hernández-Illán E, Rodríguez-Soler M, et al. Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer. *J Med Genet* 2015;52:498–502.
 48. Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. *Genes Chromosomes Cancer* 2009;48:737–744.
 49. Pineda M, Mur P, Iñiesta MD, et al. MLH1 methylation screening is effective in identifying epimutation carriers. *Eur J Hum Genet* 2012;20:1256–1264.
 50. Crucianelli F, Tricarico R, Turchetti D, et al. MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria. *Epigenetics* 2014;9:1431–1438.
 51. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;96:261–268.
 52. van Roon EH, van Puijenbroek M, Middeldorp A, et al. Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? *BMC Cancer* 2010;10:180.
 53. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med* 2005;352:1851–1860.
 54. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. *J Clin Oncol* 2008;26:5783–5788.
 55. Pearlman R, Frankel WL, Swanson BJ, et al. Prospective statewide study of universal screening for hereditary colorectal cancer: the Ohio Colorectal Cancer Prevention Initiative. *JCO Precis Oncol* 2021;5:PO.20.00525.
 56. Deng G, Chen A, Hong J, et al. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. *Cancer Res* 1999;59:2029–2033.
 57. Deng G, Peng E, Gum J, et al. Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. *Br J Cancer* 2002;86:574–579.
 58. Newton K, Jorgensen NM, Wallace AJ, et al. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch syndrome (HNPCC). *J Med Genet* 2014;51:789–796.
 59. Dámaso E, Castillejo A, Arias MDM, et al. Primary constitutional MLH1 epimutations: a focal epigenetic event. *Br J Cancer* 2018;119:978–987.
 60. Hitchins MP, Ward RL. Erasure of MLH1 methylation in spermatozoa—implications for epigenetic inheritance. *Nat Genet* 2007;39:1289.
 61. Wong JJ, Hawkins NJ, Ward RL, et al. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. *Mod Pathol* 2011;24:396–411.
 62. Dámaso E, Canet-Hermida J, Vargas-Parra G, et al. Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation. *Clin Epigenetics* 2019;11:171.



See JNCCN.org for supplemental online content.

Supplemental online content for:

Constitutional *MLH1* Methylation Is a Major Contributor to Mismatch Repair–Deficient, *MLH1*-Methylated Colorectal Cancer in Patients Aged 55 Years and Younger

Megan P. Hitchins, PhD; Estela Dámaso, PhD; Rocio Alvarez, MS; Lisa Zhou, MS; Yajing Hu, PhD; Marcio A. Diniz, PhD; Marta Pineda, PhD; Gabriel Capella, MD, PhD; Rachel Pearlman, MS, CGC; and Heather Hampel, MS, CGC

J Natl Compr Canc Netw 2023;21(7):743–752.e11

eAppendix 1: Supplemental Information

- eFigure 1:** Overall Strategy for Patient Selection and Numbers for Constitutional *MLH1* Methylation Screening
- eFigure 2:** Analytical Sensitivity and Linearity of CpG Pyrosequencing to Measure *MLH1* Methylation
- eFigure 3:** Analytical Sensitivity and Linearity of the Semiquantitative Real-Time Methylation-Specific PCR Assay Used to Screen for Constitutional *MLH1* Methylation
- eFigure 4:** Illustrative Amplification Profiles From Real-Time Methylation-Specific PCR Assay for the Detection and Semiquantification of Constitutional *MLH1* Methylation
- eFigure 5:** Postamplification Melt Curves Indicating Specificity for *MLH1* Methylation After qMSP
- eFigure 6:** Clonal Bisulfite Sequencing Confirms the Presence of Constitutional *MLH1* Methylation Across Individual Alleles in Blood DNA
- eFigure 7:** Posterior Probability That the Rate of Detection of Constitutional *MLH1* Methylation Will Exceed the Acceptable Threshold for Various Detection Rates Under Selected Ages
- eTable 1:** Posterior Probability That Positive Detection of Constitutional *MLH1* Methylation Is >X% in Patients With MMRd, *MLH1*-Methylated CRC

eAppendix 1. Supplemental Information

Patients with colorectal cancer (CRC) were selected from the Columbus-area HNPCC study (Columbus) cohort and the Ohio Colorectal Cancer Prevention Initiative (OCCPI) cohort, who were prospectively recruited to assess universal screening for mismatch repair deficiency (MMRd), Lynch syndrome (LS), and other hereditary cancer conditions. The overall process of selection of cases and sample size for this study is illustrated in the CONCORD diagram in supplemental eFigure 1.

Analytical Sensitivity of the Pyrosequencing Assay for the Detection of *MLH1* Methylation

To determine the limit of detection (LoD) of the *MLH1* pyrosequencing assay, at which a methylation-positive test result would be designated, a dilution series of expected methylation levels was generated and assayed. DNA from the *MLH1*-hypermethylated RKO CRC cancer line (American Type Culture Collection) was mixed with DNA from unmethylated peripheral blood lymphocytes of a healthy subject to a total of 500 ng of DNA in proportions of RKO:PBL of 100:0 (RKO only), 75:25, 50:50, 25:75, 10:90, 5:95, 2.5:97.5, 2:98, 1:99, and 0:100 (PBL only). The average methylation level of the hypermethylated RKO was 97%, so the expected values for *MLH1* methylation in the dilution series were adjusted accordingly. This series emphasized the lower range of values (0%–5% RKO) for increased precision in the range we anticipated the methylation-positive threshold value would lie. Each 500-ng sample in the dilution series was bisulfite converted using the EZ DNA Methylation-Gold Kit (Zymo Research). A 50-ng aliquot of bisulfite-converted dilution point was input into each PCR, purified, and pyrosequenced in triplicate in 3 separate experiments. The actual values of *MLH1* methylation measured were plotted against the expected methylation values (supplemental eFigure 2). There was strong correlation between the actual versus expected values across the full 0% to 97% methylation range ($R^2 > 0.95$) (supplemental eFigure 2A). The LoD of methylation distinguishable above background noise was 2.3% (actual value) for the RKO:PBL 2.5%:97.5% dilution point with an expected value of 2.4% (supplemental eFigure 2B). This was also the lowest dilution point for which each of the 5 individual CpG sites within the assay gave a value ≥ 1 in all tests. Therefore, for designation of a methylation-positive test result, we applied a threshold of 2.3% average methylation detected across the 5 CpG sites measured, with each of the 5 CpG sites yielding a value ≥ 1 .

Analytical Sensitivity of the Real-Time Methylation-Specific PCR Assay for the Detection of *MLH1* Methylation

Real-time semi-quantitative methylation-specific PCR (qMSP) for the detection of *MLH1* methylation was performed from c.-188 to c.-403 using SYBR Green fluorescent intercalating dye, followed by melt curve analysis (melt peak at $76^\circ\text{C} \pm 0.5^\circ\text{C}$ indicates methylation specificity of the amplicon). The *MLH1* qMSP was performed alongside *MYOD* as a control for sample input and integrity (same run, separate reactions). Results were considered valid if the *MYOD* control had a cycle threshold (Ct) value < 32 . Semiquantification of methylated *MLH1* was calculated against *MYOD* with reference to a commercial enzymatically (*M.SssI*) fully methylated reference sample (Universal Methylated DNA Standard, Zymo Research) to produce a percentage of methylated reference (PMR) value as follows: The $\Delta\Delta\text{Ct}$ value for each sample was calculated as $\Delta\text{Ct}_{\text{Sample}(\text{MYOD}-\text{MLH1})} - \Delta\text{Ct}_{\text{Reference}(\text{MYOD}-\text{MLH1})}$. The PMR was calculated as $2^{(\Delta\Delta\text{Ct})} \times 100$. A dilution series of fully methylated DNA diluted into unmethylated DNA was generated by diluting the *M.SssI* enzymatically methylated reference sample into PBL DNA from unmethylated healthy subjects for expected values of 75%, 50%, 25%, 10%, 5%, 1%, 0.5%, and 0.1% *MLH1* methylation, followed by bisulfite conversion. Samples were tested in triplicate on 3 separate occasions, and the PMR was measured against the 100% methylated reference sample. This qMSP assay has high analytical sensitivity, with a LoD of 0.1% *MLH1* methylation (supplemental eFigure 3), enabling the detection of low-level mosaicism.

Patient samples were considered positive for constitutional *MLH1* methylation if their blood DNA sample yielded a PMR value $\geq 0.1\%$ by qMSP. Illustrative amplification curves of the fully methylated reference sample used to calculate PMR values, as well as patient samples with positive and negative test results, are shown in supplemental eFigure 4. Illustrative postamplification melt curves indicating methylation specificity at $76^\circ\text{C} \pm 0.5^\circ\text{C}$ are shown in supplemental eFigure 5.

(continued on next page)

eAppendix 1. Supplemental Information (cont.)


Posterior Probability of Detection of Constitutional *MLH1* Methylation at Various Rates and Ages

A Bayesian approach was used to estimate the posterior distribution for the probability of positive detection of constitutional *MLH1* methylation among the selected CRC cases tested from each cohort. The number of patients with constitutional *MLH1* methylation, Y , was modeled using a *Binomial*(n, p) distribution, with n = sample size and p = probability of detection of constitutional *MLH1* methylation. A Jeffreys noninformative prior distribution, *Beta* ($1/2, 1/2$), was assumed for p , such that posterior distribution is given by *Beta*($1/2 + y, 1/2 + n - y$). Based on the posterior distributions, the probability that positive detection of constitutional *MLH1* methylation is above a given detection threshold was calculated (supplemental eFigure 7).


Actual values for posterior probability for detection of constitutional *MLH1* methylation in the 2 cohorts at age thresholds of particular interest and feasibility for screening are given in supplemental eTable 1.

Prior studies


Columbus-area HNPCC study cohort



Ohio Colorectal Cancer Prevention Initiative cohort




This study



eFigure 1. Overall strategy for patient selection and numbers for constitutional *MLH1* methylation screening in 2 population-based cohorts of incident CRC in the state of Ohio.

Abbreviations: CRC, colorectal cancer; IHC, immunohistochemistry; MMR, mismatch repair; MMRd, mismatch repair–deficient; MSI, microsatellite instability; PBL, peripheral blood leukocyte; PV, pathogenic variant.



eFigure 2. Analytical sensitivity and linearity of *MLH1* methylation to measure expected percentage methylation plotted against expected percentage methylation levels in a dilution series of the hypermethylated colorectal cancer cell line, RKO, mixed with unmethylated healthy control peripheral blood lymphocytes in designated ratios. Plotted are the means of the mean methylation values across 3 experiments, where each dilution point was assayed in triplicate. Error bars show the SD of the means across the 3 experiments. **(A)** Full range of measured values versus expected values from 0% to 97%, showing a strong linear correlation between the actual values measured and the expected values ($R^2 > 0.95$). **(B)** Expanded view of the range of values between 0% and 10%, also showing a strong correlation between actual and expected values ($R^2 > 0.95$). Some background noise was consistently observed, even in the unmethylated sample (0% expected). The lowest actual value of methylation measured that was distinguishable above background noise and with nonoverlapping standard error bars was 2.3% (expected value 2.4%).




Figure 3. Analytical sensitivity and linearity of the semiquantitative real-time methylation-specific PCR assay used to screen for constitutional *MLH1* methylation, particularly low-level mosaic methylation. **(A)** Full range of measured values versus expected values from 0% to 100%, showing a strong linear correlation between the measured values and the expected values ($R^2 > 0.99$), when calculated as a PMR. **(B)** Expanded view of the range of values between 0% and 5%, also show a strong correlation between measured and expected values ($R^2 > 0.99$). The limit of detection was a PMR of 0.1%.

Abbreviation: PMR, percentage of methylated reference.




Figure 4. Illustrative amplification profiles from real-time methylation-specific PCR assay for the detection and semiquantification of constitutional *MLH1* methylation. Blue curve shows amplification of the *MYOD* locus, which amplified regardless of methylation status and serves as the input control for sample sufficiently and integrity. Orange curve shows amplification of the *MLH1* locus only if it is methylated (*mMLH1*), because this assay is methylation-specific. Green horizontal line shows the cycle threshold at which levels of *MYOD* and *mMLH1* are measured. **(A, B)** Samples from CRC cases OCCPI-1 and OCCPI-2, which were positive for constitutional *MLH1* methylation at different levels (pyrosequencing and clonal bisulfite sequencing showed OCCPI-1 was mosaic and OCCPI-2 was hemiallelic). **(C)** OCCPI-21, a case that tested negative for constitutional *MLH1* methylation, illustrating the *mMLH1* line lies beneath the green cycle threshold. **(D)** *M.SssI* fully methylated human DNA, which served as the reference sample for calculating percentage of methylated reference. Abbreviations: CRC, colorectal cancer; OCCPI, Ohio Colorectal Cancer Prevention Initiative; RFU, relative fluorescence units.





Figure 5. Postamplification melt curves indicating specificity for *MLH1* methylation after qMSP. **(A, B)** Samples for which qMSP amplification products were generated from methylated *MLH1* templates, and melt curves of the amplification products showed peak melt temperature of 76°C. **(C)** Sample that did not generate a qMSP amplification product, because it was negative for *MLH1* methylation, but low levels of primer dimer may have been present. The melt curve was not measured, because this was below the threshold level. **(D)** The fully methylated reference sample provided the reference melt peak temperature at which methylated products were measured. The bump to the left of the peak is produced by primer dimers or other nonspecific binding.

Abbreviations: OCCPI, Ohio Colorectal Cancer Prevention Initiative; qMSP, real-time methylation-specific PCR; RFU, relative fluorescence units.



eFigure 6. Clonal bisulfite sequencing confirms the presence of constitutional *MLH1* methylation across individual alleles in blood DNA. The methylation status at 16 consecutive CpG sites (circles) across a fragment of the *MLH1* CpG island promoter region from c.-48 to c.-370 (GenBank accession no. NG_007109.2) is shown within individual bisulfite-sequenced alleles (horizontal lines) in the blood DNA from CRC cases (as labeled) who tested positive for methylation by the CpG pyrosequencing and real-time methylation-specific PCR screening assays. The *MLH1* promoter fragment encompassed the common promoter SNP c.-93G>A (rs1800734), enabling the demonstration of allele-specific methylation in heterozygotes. **(A)** Columbus cohort cases. Columbus-1 had just ~1% alleles methylated, indicating low-level mosaicism. Columbus-2 had ~9% methylated alleles sequenced, whereas pyrosequencing measured higher methylation levels at 27%, indicating mosaicism. Columbus-6 had hemiallelic methylation (~50% alleles methylated), consistent with pyrosequencing (47.6% methylation) and epimutation of a single parental allele. Columbus-65 was heterozygous at SNP c.-93G>A, and methylation was specific to ~11% of alleles bearing the “A” genotype, indicating monoallelic mosaic methylation in up to 11% of leukocytes.

Abbreviations: Columbus, Columbus-area HNPCC study; CRC, colorectal cancer; SNP, single-nucleotide polymorphism.

(continued on next page)




Figure 6 (cont.). Clonal bisulfite sequencing confirms the presence of constitutional MLH1 methylation across individual alleles in blood DNA. The methylation status at 16 consecutive CpG sites (circles) across a fragment of the MLH1 CpG island promoter region from c.-48 to c.-370 (Gen-Bank accession no. NG_007109.2) is shown within individual bisulfite-sequenced alleles (horizontal lines) in the blood DNA from CRC cases (as labeled) who tested positive for methylation by the CpG pyrosequencing and real-time methylation-specific PCR screening assays. The MLH1 promoter fragment encompassed the common promoter SNP c.-93G.A (rs1800734), enabling the demonstration of allele-specific methylation in heterozygotes. **(B)** OCCPI cohort cases. OCCPI-1 was heterozygous for SNP c.-93G>A with ~20% of “G” alleles methylated. This was consistent with 4.2% methylation measured by pyrosequencing and together indicate mosaic monoallelic methylation present in ~8%–10% of leukocytes. OCCPI-2, -10, and -15 had hemiallelic methylation (~50% alleles methylated), consistent with 46%–50% methylation levels measured by pyrosequencing and epimutation affecting a single parental allele.

Abbreviations: CRC, colorectal cancer; OCCPI, Ohio Colorectal Cancer Prevention




Figure 7. Posterior probability that the rate of detection of constitutional *MLH1* methylation will exceed the acceptable threshold for various detection rates under selected ages. Posterior probabilities are very high (y axis) that acceptable detection rates of 10% (x axis) will be exceeded by screening in patients aged <50, <55, and <60 years in the Columbus cohort and patients aged <50 and <55 years in the OCCPI cohort. Abbreviations: Columbus, Columbus-area HNPCC study; OCCPI, Ohio Colorectal Cancer Prevention Initiative.

eTable 1. Posterior Probability That Positive Detection of Constitutional *MLH1* Methylation Is >X% in Patients With MMRd, *MLH1*-Methylated CRC

	Columbus Cohort	OCCPI Cohort
Overall (all ages)		
1%	0.993	0.778
5%	0.387	0.001
10%	0.020	0.000
Age <60 y		
1%	1.00	1.000
5%	0.999	0.964
10%	0.991	0.724
25%	0.862	0.052
Age ≤55 y ^a		
1%	1.000	1.000
5%	1.000	0.997
10%	0.999	0.956
25%	0.984	0.464
Age <55 y ^a		
1%	1.000	1.000
5%	1.000	0.988
10%	0.999	0.913
25%	0.984	0.399
Age <50 y		
1%	1.000	1.000
5%	0.999	0.981
10%	0.994	0.911
25%	0.942	0.529

Abbreviations: CRC, colorectal cancer; Columbus, Columbus-area HNPCC study; MMRd, mismatch repair-deficient; OCCPI, Ohio Colorectal Cancer Prevention Initiative.

^aThere were no cases aged 55 years in the Columbus cohort; therefore, posterior probabilities were the same for <55 years and ≤55 years in this cohort.